ETON Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Eton Pharmaceuticals Inc is not a strong buy at the moment for a beginner investor with a long-term strategy. Despite positive long-term growth projections and favorable analyst ratings, the recent price drop, CFO departure, and mixed financial performance suggest waiting for more stability before investing.
The MACD is negatively expanding (-0.143), RSI is neutral at 38.426, and the stock is trading below key pivot levels (current price: 24.32, Pivot: 25.784). While moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the overall technical indicators suggest a bearish short-term trend.
and strong long-term growth projections, including revenue targets of $500M by
The company has also demonstrated strong YoY revenue growth (+82.72%) and improved gross margins (+10.72%).
The recent departure of the CFO has raised concerns among investors, contributing to a significant price drop (-9.42% in regular market trading). Additionally, net income and EPS have significantly declined (-347.99% and -400.00% YoY, respectively), reflecting financial instability. The stock also lacks recent congress trading data and has no strong proprietary trading signals.
In Q4 2025, revenue increased by 82.72% YoY to $21.28M, and gross margins improved to 61.56%. However, net income dropped by -347.99% YoY to $1.48M, and EPS fell by -400.00% YoY to 0.06, indicating profitability challenges.
Analysts maintain a strong buy rating with price targets raised to $31, $35, and $52, citing long-term growth potential, strong revenue visibility, and a path to financial maturity by 2030.
